Skip to main content

Advertisement

SpringerLink
Log in

Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Gallbladder cancers have a very poor prognosis without specific molecular marker being identified. In this study we studied PUMA, c-Myb and p53 expression in benign and malignant lesions of gallbladder and analyzed their clinicopathological significance.

Method

Immunohistochemical staining of PUMA, c-Myb and p53 protein was performed in 108 gallbladder adenocarcinomas, 46 peritumoral tissues, 15 polyps, and 35 chronic cholecystitis.

Results

We demonstrated that the percent of positive PUMA, c-Myb and p53 expression was significantly higher in gallbladder adenocarcinomas than in peritumoral tissues, polyps and chronic cholecystitis (p < 0.05 or 0.01). Benign gallbladder epithelium with positive PUMA, c-Myb or p53 expression showed moderately or severely atypical hyperplasia. The percent of positive PUMA, c-Myb and p53 expression was significantly higher in the cases having poorly differentiated adenocarcinoma with large tumor mass, lymph node metastasis and high invasiveness than cases with well-differentiated adenocarcinoma with small tumor mass and without metastasis and invasiveness (p < 0.05 or p < 0.01). The percent of positive PUMA, c-Myb and p53 expression was significantly higher in cases with radical resection than without resection (p < 0.05). Univariate Kaplan–Meier analysis showed that PUMA, c-Myb and p53 expression was associated with decreased overall survival (p < 0.05 or p < 0.01). Multivariate Cox regression analysis showed that PUMA, c-Myb or p53 expression was a poor-prognostic predictor in gallbladder adenocarcinoma.

Conclusion

PUMA, c-Myb and p53 expression closely relates to the carcinogenesis, fast-progression, easy-metastasis, high-invasion, and poor-prognosis in gallbladder adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Randi G, Franceschi S, La Vecchia C (2006) Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 118:1591–1602

    Article  PubMed  CAS  Google Scholar 

  2. Jayaraman S, Jarnagin WR (2010) Management of gallbladder cancer. Gastroenterol Clin North Am 39:331–342

    Article  PubMed  Google Scholar 

  3. Srivastava K, Srivastava A, Sharma KL et al (2011) Candidate gene studies in gallbladder cancer: a systematic review and meta-analysis. Mutat Res 728:67–79

    Article  PubMed  CAS  Google Scholar 

  4. Gatto M, Bragazzi MC, Semeraro R et al (2010) Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 42:253–260

    Article  PubMed  CAS  Google Scholar 

  5. Zhu AX, Hezel AF (2011) Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities. Hepatology 53:695–704

    Article  PubMed  CAS  Google Scholar 

  6. Tucek S, Tomasek J, Halámkova J (2010) Bile duct malignancies. Klin Onkol 23:231–241

    PubMed  CAS  Google Scholar 

  7. Legan M, Luzar B, Marolt VF et al (2006) Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions. World J Gastroenterol 12:3425–3429

    PubMed  CAS  Google Scholar 

  8. Chuang SC, Lee KT, Tsai KB et al (2004) Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. World J Surg 28:995–1000

    Article  PubMed  Google Scholar 

  9. Puhalla H, Kandioler D, Ludwig C et al (2004) p53 analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry. Anticancer Res 24:1201–1206

    PubMed  CAS  Google Scholar 

  10. Kandioler-Eckersberger D, Ludwig C, Rudas M et al (2000) TP 53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6:50–56

    PubMed  CAS  Google Scholar 

  11. Kandioler-Eckersberger D, Kappel S, Mittelbock M et al (1999) The TP 53 genotype but not the immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III nonsmall cell lung cancer. J Thorac Cardiovasc Surg 117:744–750

    Article  PubMed  CAS  Google Scholar 

  12. Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F et al (2002) TP 53 genotype but not p53 immunohistochemical result predicts response to preoperative short term radiotherapy in rectal cancer. Ann Surg 235:493–498

    Article  PubMed  Google Scholar 

  13. Gannon JV, Greaves R, Iggo R et al (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595–1602

    PubMed  CAS  Google Scholar 

  14. Morton JP, Timpson P, Karim SA et al (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 107:246–251

    Article  PubMed  CAS  Google Scholar 

  15. Middelburg R, de Haas RR, Dekker H et al (2005) Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin Cancer Res 11:1863–9186

    Article  PubMed  CAS  Google Scholar 

  16. Villunger A, Michalak EM, Coultas L et al (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302:1036–1038

    Article  PubMed  CAS  Google Scholar 

  17. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B (2001) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7:673–682

    Article  PubMed  CAS  Google Scholar 

  18. Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7:683–694

    Article  PubMed  CAS  Google Scholar 

  19. Liu Z, Lu H, Shi H et al (2005) PUMA overexpression induces reactive oxygen species generation and proteasome-mediated stathmin degradation in colorectal cancer cells. Cancer Res 65:1647–5164

    Article  PubMed  CAS  Google Scholar 

  20. Li J, Lee B, Lee AS (2006) Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem 281:7260–7270

    Article  PubMed  CAS  Google Scholar 

  21. Cheng EH, Wei MC, Weiler S et al (2001) BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8:705–711

    Article  PubMed  CAS  Google Scholar 

  22. Hacki J, Egger L, Monney L et al (2000) Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2. Oncogene 19:2286–2295

    Article  PubMed  CAS  Google Scholar 

  23. Yu J, Yue W, Wu B et al (2006) PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin Cancer Res 12:2928–2936

    Article  PubMed  Google Scholar 

  24. Yu F, Watts RN, Zhang XD et al (2006) Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent phenoxodiol-induced apoptosis of human melanoma cells. Anticancer Drugs 17:1151–1161

    Article  PubMed  CAS  Google Scholar 

  25. Liu HF, Hsiao PW, Chao JI (2008) Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells. Chem Biol Interact 176:48–57

    Article  PubMed  CAS  Google Scholar 

  26. Tanikawa J, Nomura T, Macmillan EM et al (2004) p53 suppresses c-Myb-induced trans-activation and transformation by recruiting the corepressor mSin3A. J Biol Chem 279:55393–55400

    Article  PubMed  CAS  Google Scholar 

  27. Schmidt M, Nazarov V, Stevens L et al (2000) Regulation of the resident chromosomal copy of c-myc by c-Myb is involved in myeloid leukemogenesis. Mol Cell Biol 20:1970–1981

    Article  PubMed  CAS  Google Scholar 

  28. Kowenz-Leutz E, Herr P, Niss K et al (1997) The homeobox gene GBX2, a target of the myb oncogene, mediates autocrine growth and monocyte differentiation. Cell 91:185–195

    Article  PubMed  CAS  Google Scholar 

  29. Kanei-Ishii C, Tanikawa J, Nakai A et al (1997) Activation of heat shock transcription factor 3 by c-Myb in the absence of cellular stress. Science 277:246–248

    Article  PubMed  CAS  Google Scholar 

  30. Weston K (1999) Reassessing the role of C-MYB in tumorigenesis. Oncogene 18:3034–3038

    Article  PubMed  CAS  Google Scholar 

  31. Ramsay RG, Gonda TJ (2008) MYB function in normal and cancer cells. Nat Rev Cancer 8:523–534

    Article  PubMed  CAS  Google Scholar 

  32. Sala A, Casella I, Grasso L et al (1996) Apoptotic response to oncogenic stimuli: cooperative and antagonistic interactions between c-myb and the growth suppressor p53. Cancer Res 56:1991–1996

    PubMed  CAS  Google Scholar 

  33. Tanikawa J, Ichikawa-Iwata E, Kanei-Ishii C et al (2000) p53 suppresses the c-Myb-induced activation of heat shock transcription factor 3. J Biol Chem 275:15578–15585

    Article  PubMed  CAS  Google Scholar 

  34. Yamagiwa H, Tomiyama H, Yoshimura H (1986) Histogenesis of carcinoma of gallbladder. Histolohical study of serial sections of 1000 cases of resected gallbladder. Rinsho Byori 34:475–480

    PubMed  CAS  Google Scholar 

  35. Dowling GP, Kelly JK (1986) The histogenesis of adenocarcinoma of the gallbladder. Cancer 58:1702–1708

    Article  PubMed  CAS  Google Scholar 

  36. Sanada Y, Yoshida K, Ohara M et al (2007) Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res 13:105–113

    Article  PubMed  Google Scholar 

  37. Chang HJ, Yoo BC, Kim SW et al (2007) Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 13:326–335

    Article  PubMed  CAS  Google Scholar 

  38. Augenlicht LH (2001) Clinical response to fluorouracil and p53. N Engl J Med 345:1065

    Article  PubMed  CAS  Google Scholar 

  39. Watanabe T, Wu TT, Catalano PJ et al (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196–1206

    Article  PubMed  CAS  Google Scholar 

  40. Puhalla H, Wild T, Filipits M et al (2001) Der prognostische Wert der p53 Immunhistochemie beim Gallenblasenkarzinom. Acta Chir Austr 33:85–88

    Article  Google Scholar 

  41. Quan ZW, Wu K, Wang J et al (2001) Association of p53, p16 and vascular endothelial growth factor expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 193:380–383

    Article  PubMed  CAS  Google Scholar 

  42. Diamantis I, Karamitopoulou E, Perentes E et al (1995) p53 protein immunoreactiviy in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Histopathology 22:774–779

    CAS  Google Scholar 

  43. Kandioler-Eckersberger D, Kappel S, Mittelbock M et al (1999) The TP 53 genotype but not the immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III nonsmall cell lung cancer. J Thorac Cardov Sur 117:744–750

    Article  CAS  Google Scholar 

  44. Ray RM, Bhattacharya S, Johnson LR (2011) Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis 16:35–44

    Article  PubMed  CAS  Google Scholar 

  45. Sinicrope FA, Rego RL, Okumura K et al (2008) Prognostic impact of bin, puma, and noxa expression in human colon carcinomas. Clin Cancer Res 14:5810–5818

    Article  PubMed  CAS  Google Scholar 

  46. Karst AM, Dai DL, Martinka M et al (2005) PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 24:1111–1116

    Article  PubMed  CAS  Google Scholar 

  47. Diallo JS, Aldejmah A, Mouhim AF et al (2007) NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res 13:7044–7052

    Article  PubMed  CAS  Google Scholar 

  48. Jansson A, Arbman G, Sun XF (2004) mRNA and protein expression of PUMA in sporadic colorectal cancer. Oncol Rep 12:1245–1249

    PubMed  CAS  Google Scholar 

  49. Coutinho-Camillo CM, Lourenço SV, Nishimoto IN et al (2010) Expression of Bcl-2 family proteins and association with clinicopathological characteristics of oral squamous cell carcinoma. Histopathology 57:304–316

    Article  PubMed  Google Scholar 

  50. Brabender J, Lord RV, Danenberg KD et al (2001) Increased C-myb mRNA expression in Barretts esophagus and Barretts-associated adenocarcinoma. J Surg Res 99:301–306

    Article  PubMed  CAS  Google Scholar 

  51. Gonda TJ, Leo P, Ramsay RG (2008) Estrogen and MYB in breast cancer: potential for new therapies. Expert Opin Biol Ther 8:713–717

    Article  PubMed  CAS  Google Scholar 

  52. Wilkins HR, Doucet K, Duke V et al (2010) Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing C-myb protein, and decreasing transcription of the anti-apoptosis protein bcl-2. Tumor Biol 31:16–22

    Article  CAS  Google Scholar 

  53. Yang H, Huang ZZ, Wang J et al (2001) The role of C-myb and SP1 in the up-regulation of methionine adenosyl transferase 2A gene expression in human hepatocellular carcinoma. FASEB J 15:1507–1516

    Article  PubMed  CAS  Google Scholar 

  54. Narnberg W, Artue M, Nawrath M et al (1995) Human C-myb is expressed in cervical carcinomas and transactivates the HPV-16 promoter. Cancer Res 55:4432–4437

    Google Scholar 

Download references

Conflict of interest

All of the authors declared no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Geriatric Surgery, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China

    Guo-shun Shu

  2. Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China

    Fang Lv, Zhu-lin Yang & Xiong-ying Miao

Authors
  1. Guo-shun Shu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fang Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhu-lin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiong-ying Miao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhu-lin Yang.

About this article

Cite this article

Shu, Gs., Lv, F., Yang, Zl. et al. Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances. Int J Clin Oncol 18, 641–650 (2013). https://doi.org/10.1007/s10147-012-0431-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-012-0431-7

Keywords

Search

Navigation